Lung Neoplasms
Conditions
Keywords
Inflammation, Glasgow score, Intensive Care Unit, Emergency
Brief summary
Systemic inflammation is a potential prognostic factor in cancer. Inflammation scores as the Glasgow score have been tested in cancer and specifically in lung cancer patients. The aim of the study is to look at the prognostic and predictive value of inflammation during cancer evolution, on the risk of complications leading to ICU admission and the risk of death.
Detailed description
Patients with newly diagnosed lung cancer will be eligible. All patients will have a blood sampling allowing testing inflammation and cytokine analyses at diagnosis, during work-up and in case of complication.
Interventions
None listed
Sponsors
Jules Bordet Institute
European Lung Cancer Working Party
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Lung neoplasms irrespective of stage, histology
Exclusion criteria
* Previously treated lung neoplasms * A history of prior malignant tumour, except non-melanoma skin cancer or in situ carcinoma of the cervix or cured malignant tumour (more than 5 year disease-free interval)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Survival | Measured from diagnosis until death or last date known to be alive, or at least 48 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Complications leading to emergency/ICU | From inclusion until death, or a least 48 months | Recording any complication leading to consultation at the emergency department or admission into the intensive care unit |
Countries
Belgium
Outcome results
None listed